drugset / Trial / NCT02849548
Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder
Phase 4
Completed
27 enrolled
Howard University
Georgetown-Howard Universities Center for Clinical and Translational Science · collabNational Institute of Mental Health (NIMH) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to examine effects of blocking the orexin system with suvorexant after exposure-based intervention for posttraumatic stress disorder (PTSD) on sleep, PTSD symptoms, and intersession habituation.
Timeline
- Start
- 2017-01-03
- Primary completion
- 2021-05-17
- Completion
- 2021-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Suvorexant | Small molecule | 10 mg | — |
| Subject | Suvorexant | Small molecule | 20 mg | — |